免疫2号方干预艾滋病患者免疫重建的临床及机制研究
摘要
艾滋病全称为获得性免疫缺陷综合征(acquired immunodeficiency syndrome,AIDS),由感染人免疫缺陷病毒(human immunodeficiency virus,HIV)而引起,是一种严重危害人类健康的致死性传染病。高效抗逆转录病毒疗法(highly active anti-retroviral therapy,HAART)是目前临床公认的较为有效的治疗方法,可最大限度地抑制艾滋病毒复制,有效降低血浆病毒载量,并在一定程度上促进患者的免疫功能重建。然而,这种免疫重建常常是不完全的,且不同个体间存在很大差异。如何解决HAART后免疫重建不全的问题,发现有效的治疗及干预手段至关重要。
中医药从整体调节角度入手,对人体免疫功能具有独特的调节作用,以免疫重建作为中医药干预艾滋病治疗的切入点已成为当前艾滋病领域的研究热点。因此本研究从艾滋病免疫重建的文献和理论梳理入手,确定研究的目标及干预手段,继之以临床流行病学调查结果为支持,深入了解我国HAART治疗的临床特点,最后采用随机、盲法、安慰剂对照的RCT试验对免疫2号方的临床疗效进行了验证,同时在T细胞表面受体基因重排及免疫信号分子通路方面进行了初步的机制探讨,概要如下：
1国内HAART治疗对艾滋病免疫重建及死亡率的影响研究
目的
了解我国近年来接受HAART疗法的人群特征及HAART治疗对艾滋病患者免疫重建和死亡率的影响,为下一步的临床研究寻找目标人群。
方法
用描述流行病学方法对广西柳州龙潭医院2005年1月至2009年12月5年期间首次接受HAART治疗的2644例艾滋病病例进行流行病学分析,比较不同性别患者年龄、种族以及危险因素的年度分布趋势,描述CD4细胞计数在治疗前后的分布变化,计算标准化死亡率比(SMRs),进行生存分析。
结果
(1)2005年至2009年,发病患者多数为男性(1740,65.81%),其中30～39岁组最多,与女性患者分布类似,不同之处在于女性20～29岁组在最近3年中有显著增长。性接触成为主要传播方式,2009年占接受治疗人群的85.2%(612/718)。
(2)治疗超过1年的患者中,CD4涨幅超过10%的有1064例患者(53%、不包括死亡和失访患者),262例(13%,262/2004)患者治疗后CD4反下降10%以上,免疫重建不全发生率为188例,占17.42%。
(3)SMR在20-29岁组最高,为62.42,(95%CI41.44-83.40),而在>=60岁组最低,为1.55(95%CI0.9-2.20)。169例(6.39%,169/2644)患者在随访中死亡,死亡率为3.99/100人年。以不同传播途径分层：静脉吸毒患者死亡率52/475(10.9%),性传播患者死亡率105/2015(5.2%),其他因素感染者死亡率12/154(7.8%)(p=0.000)。
结论
我国HAART治疗已经极大减少了AIDS所致死亡率,但免疫重建不全患者仍占17.42%,尚需要更多有效的免疫调节手段来弥补HAART治疗的缺陷。
2免疫2号方干预艾滋病患者免疫重建的临床及机制研究
目的
观察免疫2号方对AIDS患者HAART后免疫重建功能的影响,并探讨该疗法对机体免疫调节的作用机制。
方法
采用随机、双盲、安慰剂对照的临床试验设计原则,264例HAART后免疫重建不全患者随机分为治疗组(131例)和对照组(133例),分别采用免疫2号方联合HAART治疗和安慰剂联合HAART治疗6个月,观察两组治疗前后外周血CD4+、CD4CD45RA+、CD4CD45RO+细胞数量的改变,以及两组治疗前后症状、体征积分及改善率的变化,评价其免疫重建有效率。同时对TCRVβ基因多样性的改变进行检测,并采用Toll样受体(Toll-like receptors, TLR)信号转导基因芯片检测免疫2号方联合HAART对TLR信号传导通路的影响。
结果
符合纳入标准的病例264例,试验过程中有3例因不良反应脱落,25例自行退出,1例数据不完全,2例因未服用药物剔除。最后完成研究233例,治疗组116例,对照组117例。
(1)两组免疫重建有效率及免疫细胞计数比较：干预1个月后,治疗组有效率(18.97%)显著高于对照组(9.40%),(p=0.0209)；疗后3月,治疗组(27.59%)仍然高于对照组(22.22%)(p=0.3076)；疗后6月,治疗组有效率(34.48%)显著优于对照组(21.37%),差异有统计学意义(p=0.0217)。CD4+、CD4CD45RA+、CD4CD45RO+绝对计数治疗组增加幅度显著高于对照组(p<0.05)。
(2)两组症状体征改善率及总积分比较：治疗6月以后,两组各项症状、体征均有所改善甚至消失。总积分组内比较差异均有统计学意义(P<0.05),治疗组的总积分改善程度与对照组相比效果更好(P<0.05)。治疗组在改善患者乏力、肌关节痛、皮肤瘙痒、气短等症状时疗效明显优于对照组,差异有统计学意义(P<0.05)。
(3)两组病毒载量变化比较：治疗前、治疗3月、治疗6月,两组病毒载量变化组间比较差异无统计学意义,组内前后配对检验结果比较差异无统计学意义。
(4)安全性分析：两组均有部分患者发生不良事件,治疗组不良事件发生率为3.08%,对照组6.25%,组间比较差异无统计学意义(P=0.2263)。治疗前后,血常规、尿常规、心电图、B超、胸片检查结果均无明显变化。
(5)TCRVP基因多样性改变比较结果显示：①HAART治疗后一年免疫重建不全患者的TCRVβ多个家族的扫描图高斯分布被打破,并发生TCR谱系的偏移,经半年中药联合HAART治疗后,偏移的TCR谱系有所恢复。②以试剂盒提供的定量分析软件计算的距离D(distance)值来量化评价,两组D值改变无明显差异(p>0.05),但联合中药能减少数据的变异性。③CD4+T细胞计数与TCRVβ基因多样性改变两者存在显著的相关关系(r=-0.772,P=0.000)。④相对于正常人,患者一些Vβ内出现了明显的CDR3区的单寡克隆扩增情况,经过治疗后各家族单寡克隆情况有不同程度的改善和恢复。其中,9,11,21,22四个家族的D值两组治疗后均比治疗前下降,治疗组下降幅度较对照组在21,22两个家族更为显著(P<0.05)。治疗组显著降低第18家族D值,而对照组则显著增加(P<0.05)。
(6)TLR信号转导通路分析结果显示：筛选出与艾滋病免疫重建不全有关的基因显著上调≥2倍的有5个(如干扰素-γ、IL-6、IL-8等),下调≥2倍的基因有4个(如TLR9、NF-KB等),通路上游以基因下调改变为主(如TLR9、TOLUP、TRIF、IRAK1、TAB1、p105),下游则多为上调改变(如AP-1、IL-6、IL-8)。联合免疫2号方干预后,相关基因显著上调≥2倍的有7个(如IL-2、IL-10、TLR1等),无显著下调基因,对通路上游基因的上调作用最为显著(如TLR1、CD14、TRAF6).
结论
(1)中药免疫2号方对HAART后艾滋病患者CD4+T细胞免疫重建以及症状体征具有较为明确的疗效,其在改善患者乏力、肌关节痛、皮肤瘙痒、气短等症状方面有较好效果,CD45RA、CD45RO细胞亚群均有一定程度的恢复。
(2)免疫2号方具有良好的安全性,无明显不良反应。
(3)机制研究表明中药复方对于TCRVβ各家族单寡克隆情况有不同程度的改善和恢复,提示中医药可能促进T细胞部分受体基因重排,丰富受体库,帮助机体免疫细胞有效识别病毒,减少T细胞凋亡；对于toll样受体信号通路的研究表明HAART后免疫重建不全的艾滋病患者细胞内TLR9较正常人表达低下,IRAK1、NF-κB表达下调,提示TLR9介导的信号转导系统异常是艾滋病患者免疫重建不全发生的可能机制之一；免疫2号方调节机体免疫功能的机制可能主要通过上调TLR1和CD14表达,进而引起下游一系列通路信号分子传递而实现。
AIDS (acquired immune deficiency syndrome) is a lethal disease infected by the HIV (human immunodeficiency virus) and can caused serious harm to human health. Highly active antiretroviral therapy (HAART) is now recognized as a clinically effective treatment, which can inhibit the HIV replication, effectively reduce the plasma viral load, and to some extent, reconstitute the patients' immune function. However, this immune reconstitution is often incomplete, and there is big difference between different individuals. How to solve incomplete immune reconstitution after HAART, and find effective treatment and intervention is essential.
Chinese medicine has a unique role in the regulation of human immune system. Promoting immune reconstitution by Chinese medicine has become the focus in field of AIDS research. In this study, we started by reviewing the literature and theories of AIDS and immune reconstituiton to identify research objectives and interventions, followed by clinical epidemiological study to know more about the application of HAART in China, and finally using the randomized, blinded, placebo-controlled RCT to confirm the efficacy of Mianyi No.2. At the same time, we examined the T-cell receptor gene rearrangement and TLR signaling pathways to find the molecular mechanism. The research is devided into2parts:
PartⅠ Study on effect of immune reconstitution and mortality by HAART in China
Objective
Relatively little is known regarding HIV-positive antiretoviral-naive patients among Chinese people, and how highly active antiretroviral therapy (HAART) influenced immunological outcomes and mortality of HIV positive patients in China We aimed to examine this by analysis of retrospective data
Methods
We merged data on demographics, risk behavious, CD4cell counts and dates of death based on clinical records of2644HIV-positive antiretroviral-naive patients in Liuzhou district, Guangxi Province, China from2005to2009. We analyzed the trend of HIV prevalence, and calculated standardized mortality ratios (SMRs) standardized by age and sex. CD4counts at start and the end were also compared. Kaplan-Meier methods were used to assess survival over time.
Results
From2005to2009, most follow-up was fiom men (1740,65.81%), and the men age30-39years was the most, which was similar as in women, The incidence of young women (20-29years old) was higher than that of young men.1064patients (53%,1064/2004, not including deaths, lost of follow up) had increased magnitudes of CD4more than10percent of origin count, and262patients (13%,262/2004) had10percent decreased CD4count after treatment. The rest678patients (34%,678/2004) had incomplete information. Incomplete immune reconstitution (CD4count increased less than100/ul after one year treatment) were seen in188patients, accounting for17.42%. SMR was highest in patients age20-29at62.42,(95%Q41.44-83.40), and lowest in patients age>=60at1.55(95%CI0.90-2.20).169(6.39%,169/2644) patients died during follow-up, giving a mortality incidence rate of3.99per100person years.156/2241(7.0%) patients with CD4counts of200cells/μl or less died compared with11/314(3.5%) patients with CD4counts above200cells/μl and below350cell/μl, and2/77(2.6%) patients with CD4counts above350cells/μl (p=0.073).2/475(10.9%) patients infected by drug injection died compared with105/2015(5.2%) patients infected by sexual contact and12/154(7.8%) patients by other ways (p0.000).
Conclusion
HAART has reduced mortality among patients in China with AIDS, but incomplete immune reconstitution was still seen in188patients, accounting for17.42%. We need more effective means to promote the immune reconstitution in patients after HAART.
PartⅡ Effect and related mechanism of Mianyi No.2on the Immune Reconstitution in Patients with AIDS after HAART
Objective
To observe the Mianyi No.2on the immune reconstitution in patients with AIDS after HAART, and to investigate the possible targets and mechanisms of Mianyi No.2.
Methods
A randomized, double-blind, placebo-controlled clinical trial was designed.264patients failure to immune reconstitution after HAART were randomly divided into treatment group (131cases) and control group (133cases), respectively, using Mianyi No.2plus HAART and placebo combined with HAART for6months. CD4+, CD4CD45RA+, CD4CD45RO+cell numbers, as well as the symptoms, signs and integral improvement rates were observed in order to evaluate the immune reconstitution efficiency. At the same time changes in genetic diversity ofTCRVβ and TLR signaling pathways were detected.
Results
During the trial,264cases were enrolled and randomized, among which3cases drew out for adverse reactions,2cases for not taking medicine at all, and25cases quit by themselves. There were233cases that accomplished the clinical trial, of which116cases in the experiment group and117in the control group.
Results are as follows:
1Efficacy of immune function:after the intervention for1months, the effective rate of experiment group (18.97%) was significantly higher than that in control group (9.40%),(P=0.02);3months after treatment, the effective rate of experiment group (27.59%) is still higher than that of the control group (22.22%)(P=0.31);6months after treatment, the effective rate of experiment group (34.48%) was significantly superior to the control group (21.37%)(P=0.02). CD4+, CD4CD45RA+, CD4CD45RO+count of experiment group increased significantly higher than that of control group (P<0.05).
2Efficacy of symptoms and signs:The accumulated points of symptoms and signs in treatment group had a better improvement effect compared with the control group (P=0.02), and the improvement of fatigue, muscle and joint pain, pruritus and shortness of breath in treatment group was better than control group (P<0.05).
3Efficacy of viral load:There were no significant difference in viral load between or within groups before or after treatment (p>0.05).
4Safety analysis:The incidence of adverse events occurred in some patients in both groups, the adverse event rate of experiment group was3.08%, control group6.25%(P=0.2263). There is no significant difference in changes of blood test, urine test, ECG, B-ultrasound, or chest X-ray.
5Results ofTCRVP genetic diversity change indicate that:①Gaussian distribution ofTCR V(3families in patients with incomplete immune reconstitution after one year of HAART, had been broken with the occurrence of the offset TCR lineage. After six months of treatment of Traditional Chinese medicine combined HAART, the TCR lineage has been partially restored.②Evaluated by the D (distance) value calculated by a quantitative analysis software which the kit provides, there were no significant difference in D value change (p>0.05) between the two groups, but with traditional Chinese medicine can reduce the data variability.③CD4+T cell counts had a significant correlation (r=-0.772, P=0.000)with TCRV(3genetic diversity.④Compared with the normal group, there appeared some single or oligoclonal amplification of Vβ CDR3region in the patients, which were improved or recovered after treatment Among them, D value of four families (9,11,21,22) decreased after treatment in both groups. The decrease in family21and22was significant (P<0.05) in treatment group compared with the control group. And family18was decreased in treatment group and increased significantly in control group (P<0.05).
6Changes on Toll like Receptor Signalling Pathway:There were5genes involved in the complete immune reconstruction significantly raised more than2times (such as interferon-γ, IL-6, IL-8, etc.), and4genes decreased (such as TLR9, NF-κB etc). Genetic changes in upstream were mainly down regulated (such as TLR9, TOLLIP, TRIF, IRAKI, TAB1, p105), while in downstream were mainly up regulated (such as AP-1, IL-6, IL-8). After treatment of immune No2, there were7related genes significantly raised more than2times (such as IL-2, IL-10, TLR1etc), and no genes significant decreased. Genetic changes in upstream were mainly up regulated (such as TLR1, CD14, TRAF6).
Conclusion
1Mianyi No.2can effectively improve die numbers of CD4+T cell and its subgroups, as well as the main clinical symptoms and signs of patients after HAART, such as fatigue, muscle and joint pain, skin itching, shortness ofbreath, therefore promoting immune reconstitution.
2Mianyi No.2is safe to treat AIDS disease, with no significant adverse reactions.
3Study of the mechanism showed oligoclonal of TCRVp family can get recovery in some degrees after treated by Mianyi No.2plus HAART, suggesting that the medicine may promote T-cell receptor gene rearrangement, helping immune cells to effectively identify the virus to reduce T-cell apoptosis; TLR9were expressed lowly in AIDS patients with incomplete immune reconstitution that in healthy person, and also IRAK1、NF-κB, suggesting that abnormal signal pathway mediated by TLR9maybe one of the mechanisms of incomplete immune reconstitution of AIDS. The effect of Immune No.2may be realized by up regulating TLR1and CD14expression, resulting changes of signal molecules in downstream.
中医药从整体调节角度入手,对人体免疫功能具有独特的调节作用,以免疫重建作为中医药干预艾滋病治疗的切入点已成为当前艾滋病领域的研究热点。因此本研究从艾滋病免疫重建的文献和理论梳理入手,确定研究的目标及干预手段,继之以临床流行病学调查结果为支持,深入了解我国HAART治疗的临床特点,最后采用随机、盲法、安慰剂对照的RCT试验对免疫2号方的临床疗效进行了验证,同时在T细胞表面受体基因重排及免疫信号分子通路方面进行了初步的机制探讨,概要如下：
1国内HAART治疗对艾滋病免疫重建及死亡率的影响研究
目的
了解我国近年来接受HAART疗法的人群特征及HAART治疗对艾滋病患者免疫重建和死亡率的影响,为下一步的临床研究寻找目标人群。
方法
用描述流行病学方法对广西柳州龙潭医院2005年1月至2009年12月5年期间首次接受HAART治疗的2644例艾滋病病例进行流行病学分析,比较不同性别患者年龄、种族以及危险因素的年度分布趋势,描述CD4细胞计数在治疗前后的分布变化,计算标准化死亡率比(SMRs),进行生存分析。
结果
(1)2005年至2009年,发病患者多数为男性(1740,65.81%),其中30～39岁组最多,与女性患者分布类似,不同之处在于女性20～29岁组在最近3年中有显著增长。性接触成为主要传播方式,2009年占接受治疗人群的85.2%(612/718)。
(2)治疗超过1年的患者中,CD4涨幅超过10%的有1064例患者(53%、不包括死亡和失访患者),262例(13%,262/2004)患者治疗后CD4反下降10%以上,免疫重建不全发生率为188例,占17.42%。
(3)SMR在20-29岁组最高,为62.42,(95%CI41.44-83.40),而在>=60岁组最低,为1.55(95%CI0.9-2.20)。169例(6.39%,169/2644)患者在随访中死亡,死亡率为3.99/100人年。以不同传播途径分层：静脉吸毒患者死亡率52/475(10.9%),性传播患者死亡率105/2015(5.2%),其他因素感染者死亡率12/154(7.8%)(p=0.000)。
结论
我国HAART治疗已经极大减少了AIDS所致死亡率,但免疫重建不全患者仍占17.42%,尚需要更多有效的免疫调节手段来弥补HAART治疗的缺陷。
2免疫2号方干预艾滋病患者免疫重建的临床及机制研究
目的
观察免疫2号方对AIDS患者HAART后免疫重建功能的影响,并探讨该疗法对机体免疫调节的作用机制。
方法
采用随机、双盲、安慰剂对照的临床试验设计原则,264例HAART后免疫重建不全患者随机分为治疗组(131例)和对照组(133例),分别采用免疫2号方联合HAART治疗和安慰剂联合HAART治疗6个月,观察两组治疗前后外周血CD4+、CD4CD45RA+、CD4CD45RO+细胞数量的改变,以及两组治疗前后症状、体征积分及改善率的变化,评价其免疫重建有效率。同时对TCRVβ基因多样性的改变进行检测,并采用Toll样受体(Toll-like receptors, TLR)信号转导基因芯片检测免疫2号方联合HAART对TLR信号传导通路的影响。
结果
符合纳入标准的病例264例,试验过程中有3例因不良反应脱落,25例自行退出,1例数据不完全,2例因未服用药物剔除。最后完成研究233例,治疗组116例,对照组117例。
(1)两组免疫重建有效率及免疫细胞计数比较：干预1个月后,治疗组有效率(18.97%)显著高于对照组(9.40%),(p=0.0209)；疗后3月,治疗组(27.59%)仍然高于对照组(22.22%)(p=0.3076)；疗后6月,治疗组有效率(34.48%)显著优于对照组(21.37%),差异有统计学意义(p=0.0217)。CD4+、CD4CD45RA+、CD4CD45RO+绝对计数治疗组增加幅度显著高于对照组(p<0.05)。
(2)两组症状体征改善率及总积分比较：治疗6月以后,两组各项症状、体征均有所改善甚至消失。总积分组内比较差异均有统计学意义(P<0.05),治疗组的总积分改善程度与对照组相比效果更好(P<0.05)。治疗组在改善患者乏力、肌关节痛、皮肤瘙痒、气短等症状时疗效明显优于对照组,差异有统计学意义(P<0.05)。
(3)两组病毒载量变化比较：治疗前、治疗3月、治疗6月,两组病毒载量变化组间比较差异无统计学意义,组内前后配对检验结果比较差异无统计学意义。
(4)安全性分析：两组均有部分患者发生不良事件,治疗组不良事件发生率为3.08%,对照组6.25%,组间比较差异无统计学意义(P=0.2263)。治疗前后,血常规、尿常规、心电图、B超、胸片检查结果均无明显变化。
(5)TCRVP基因多样性改变比较结果显示：①HAART治疗后一年免疫重建不全患者的TCRVβ多个家族的扫描图高斯分布被打破,并发生TCR谱系的偏移,经半年中药联合HAART治疗后,偏移的TCR谱系有所恢复。②以试剂盒提供的定量分析软件计算的距离D(distance)值来量化评价,两组D值改变无明显差异(p>0.05),但联合中药能减少数据的变异性。③CD4+T细胞计数与TCRVβ基因多样性改变两者存在显著的相关关系(r=-0.772,P=0.000)。④相对于正常人,患者一些Vβ内出现了明显的CDR3区的单寡克隆扩增情况,经过治疗后各家族单寡克隆情况有不同程度的改善和恢复。其中,9,11,21,22四个家族的D值两组治疗后均比治疗前下降,治疗组下降幅度较对照组在21,22两个家族更为显著(P<0.05)。治疗组显著降低第18家族D值,而对照组则显著增加(P<0.05)。
(6)TLR信号转导通路分析结果显示：筛选出与艾滋病免疫重建不全有关的基因显著上调≥2倍的有5个(如干扰素-γ、IL-6、IL-8等),下调≥2倍的基因有4个(如TLR9、NF-KB等),通路上游以基因下调改变为主(如TLR9、TOLUP、TRIF、IRAK1、TAB1、p105),下游则多为上调改变(如AP-1、IL-6、IL-8)。联合免疫2号方干预后,相关基因显著上调≥2倍的有7个(如IL-2、IL-10、TLR1等),无显著下调基因,对通路上游基因的上调作用最为显著(如TLR1、CD14、TRAF6).
结论
(1)中药免疫2号方对HAART后艾滋病患者CD4+T细胞免疫重建以及症状体征具有较为明确的疗效,其在改善患者乏力、肌关节痛、皮肤瘙痒、气短等症状方面有较好效果,CD45RA、CD45RO细胞亚群均有一定程度的恢复。
(2)免疫2号方具有良好的安全性,无明显不良反应。
(3)机制研究表明中药复方对于TCRVβ各家族单寡克隆情况有不同程度的改善和恢复,提示中医药可能促进T细胞部分受体基因重排,丰富受体库,帮助机体免疫细胞有效识别病毒,减少T细胞凋亡；对于toll样受体信号通路的研究表明HAART后免疫重建不全的艾滋病患者细胞内TLR9较正常人表达低下,IRAK1、NF-κB表达下调,提示TLR9介导的信号转导系统异常是艾滋病患者免疫重建不全发生的可能机制之一；免疫2号方调节机体免疫功能的机制可能主要通过上调TLR1和CD14表达,进而引起下游一系列通路信号分子传递而实现。
AIDS (acquired immune deficiency syndrome) is a lethal disease infected by the HIV (human immunodeficiency virus) and can caused serious harm to human health. Highly active antiretroviral therapy (HAART) is now recognized as a clinically effective treatment, which can inhibit the HIV replication, effectively reduce the plasma viral load, and to some extent, reconstitute the patients' immune function. However, this immune reconstitution is often incomplete, and there is big difference between different individuals. How to solve incomplete immune reconstitution after HAART, and find effective treatment and intervention is essential.
Chinese medicine has a unique role in the regulation of human immune system. Promoting immune reconstitution by Chinese medicine has become the focus in field of AIDS research. In this study, we started by reviewing the literature and theories of AIDS and immune reconstituiton to identify research objectives and interventions, followed by clinical epidemiological study to know more about the application of HAART in China, and finally using the randomized, blinded, placebo-controlled RCT to confirm the efficacy of Mianyi No.2. At the same time, we examined the T-cell receptor gene rearrangement and TLR signaling pathways to find the molecular mechanism. The research is devided into2parts:
PartⅠ Study on effect of immune reconstitution and mortality by HAART in China
Objective
Relatively little is known regarding HIV-positive antiretoviral-naive patients among Chinese people, and how highly active antiretroviral therapy (HAART) influenced immunological outcomes and mortality of HIV positive patients in China We aimed to examine this by analysis of retrospective data
Methods
We merged data on demographics, risk behavious, CD4cell counts and dates of death based on clinical records of2644HIV-positive antiretroviral-naive patients in Liuzhou district, Guangxi Province, China from2005to2009. We analyzed the trend of HIV prevalence, and calculated standardized mortality ratios (SMRs) standardized by age and sex. CD4counts at start and the end were also compared. Kaplan-Meier methods were used to assess survival over time.
Results
From2005to2009, most follow-up was fiom men (1740,65.81%), and the men age30-39years was the most, which was similar as in women, The incidence of young women (20-29years old) was higher than that of young men.1064patients (53%,1064/2004, not including deaths, lost of follow up) had increased magnitudes of CD4more than10percent of origin count, and262patients (13%,262/2004) had10percent decreased CD4count after treatment. The rest678patients (34%,678/2004) had incomplete information. Incomplete immune reconstitution (CD4count increased less than100/ul after one year treatment) were seen in188patients, accounting for17.42%. SMR was highest in patients age20-29at62.42,(95%Q41.44-83.40), and lowest in patients age>=60at1.55(95%CI0.90-2.20).169(6.39%,169/2644) patients died during follow-up, giving a mortality incidence rate of3.99per100person years.156/2241(7.0%) patients with CD4counts of200cells/μl or less died compared with11/314(3.5%) patients with CD4counts above200cells/μl and below350cell/μl, and2/77(2.6%) patients with CD4counts above350cells/μl (p=0.073).2/475(10.9%) patients infected by drug injection died compared with105/2015(5.2%) patients infected by sexual contact and12/154(7.8%) patients by other ways (p0.000).
Conclusion
HAART has reduced mortality among patients in China with AIDS, but incomplete immune reconstitution was still seen in188patients, accounting for17.42%. We need more effective means to promote the immune reconstitution in patients after HAART.
PartⅡ Effect and related mechanism of Mianyi No.2on the Immune Reconstitution in Patients with AIDS after HAART
Objective
To observe the Mianyi No.2on the immune reconstitution in patients with AIDS after HAART, and to investigate the possible targets and mechanisms of Mianyi No.2.
Methods
A randomized, double-blind, placebo-controlled clinical trial was designed.264patients failure to immune reconstitution after HAART were randomly divided into treatment group (131cases) and control group (133cases), respectively, using Mianyi No.2plus HAART and placebo combined with HAART for6months. CD4+, CD4CD45RA+, CD4CD45RO+cell numbers, as well as the symptoms, signs and integral improvement rates were observed in order to evaluate the immune reconstitution efficiency. At the same time changes in genetic diversity ofTCRVβ and TLR signaling pathways were detected.
Results
During the trial,264cases were enrolled and randomized, among which3cases drew out for adverse reactions,2cases for not taking medicine at all, and25cases quit by themselves. There were233cases that accomplished the clinical trial, of which116cases in the experiment group and117in the control group.
Results are as follows:
1Efficacy of immune function:after the intervention for1months, the effective rate of experiment group (18.97%) was significantly higher than that in control group (9.40%),(P=0.02);3months after treatment, the effective rate of experiment group (27.59%) is still higher than that of the control group (22.22%)(P=0.31);6months after treatment, the effective rate of experiment group (34.48%) was significantly superior to the control group (21.37%)(P=0.02). CD4+, CD4CD45RA+, CD4CD45RO+count of experiment group increased significantly higher than that of control group (P<0.05).
2Efficacy of symptoms and signs:The accumulated points of symptoms and signs in treatment group had a better improvement effect compared with the control group (P=0.02), and the improvement of fatigue, muscle and joint pain, pruritus and shortness of breath in treatment group was better than control group (P<0.05).
3Efficacy of viral load:There were no significant difference in viral load between or within groups before or after treatment (p>0.05).
4Safety analysis:The incidence of adverse events occurred in some patients in both groups, the adverse event rate of experiment group was3.08%, control group6.25%(P=0.2263). There is no significant difference in changes of blood test, urine test, ECG, B-ultrasound, or chest X-ray.
5Results ofTCRVP genetic diversity change indicate that:①Gaussian distribution ofTCR V(3families in patients with incomplete immune reconstitution after one year of HAART, had been broken with the occurrence of the offset TCR lineage. After six months of treatment of Traditional Chinese medicine combined HAART, the TCR lineage has been partially restored.②Evaluated by the D (distance) value calculated by a quantitative analysis software which the kit provides, there were no significant difference in D value change (p>0.05) between the two groups, but with traditional Chinese medicine can reduce the data variability.③CD4+T cell counts had a significant correlation (r=-0.772, P=0.000)with TCRV(3genetic diversity.④Compared with the normal group, there appeared some single or oligoclonal amplification of Vβ CDR3region in the patients, which were improved or recovered after treatment Among them, D value of four families (9,11,21,22) decreased after treatment in both groups. The decrease in family21and22was significant (P<0.05) in treatment group compared with the control group. And family18was decreased in treatment group and increased significantly in control group (P<0.05).
6Changes on Toll like Receptor Signalling Pathway:There were5genes involved in the complete immune reconstruction significantly raised more than2times (such as interferon-γ, IL-6, IL-8, etc.), and4genes decreased (such as TLR9, NF-κB etc). Genetic changes in upstream were mainly down regulated (such as TLR9, TOLLIP, TRIF, IRAKI, TAB1, p105), while in downstream were mainly up regulated (such as AP-1, IL-6, IL-8). After treatment of immune No2, there were7related genes significantly raised more than2times (such as IL-2, IL-10, TLR1etc), and no genes significant decreased. Genetic changes in upstream were mainly up regulated (such as TLR1, CD14, TRAF6).
Conclusion
1Mianyi No.2can effectively improve die numbers of CD4+T cell and its subgroups, as well as the main clinical symptoms and signs of patients after HAART, such as fatigue, muscle and joint pain, skin itching, shortness ofbreath, therefore promoting immune reconstitution.
2Mianyi No.2is safe to treat AIDS disease, with no significant adverse reactions.
3Study of the mechanism showed oligoclonal of TCRVp family can get recovery in some degrees after treated by Mianyi No.2plus HAART, suggesting that the medicine may promote T-cell receptor gene rearrangement, helping immune cells to effectively identify the virus to reduce T-cell apoptosis; TLR9were expressed lowly in AIDS patients with incomplete immune reconstitution that in healthy person, and also IRAK1、NF-κB, suggesting that abnormal signal pathway mediated by TLR9maybe one of the mechanisms of incomplete immune reconstitution of AIDS. The effect of Immune No.2may be realized by up regulating TLR1and CD14expression, resulting changes of signal molecules in downstream.
引文
[1]Li TS, Tubiana R, Katlama C, et al. Long-lasting recoveiy in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease [J]. Lancet,1998,351(9117):1682-1686.
[2]李扬秋.T细胞受体的研究和应用[M].人民卫生出版社,2009.1：122.
[3]林文棠.临床免疫学[M].第四军医大学出版社,2002.7：339.
[4]Hiitter q Nowak D, Mossner M, et al. Long-term control of HIV by CCRS Delta32/Delta32 stemcell transplantation[J]. N Engl J Med,2009,360(7):724-725.
[5]Imami N, Gotch F. Prospects for immune reconstitution in HTV-1 infection[J]. Clin Exp Immunol, 2002,127 (3):402-411.
[6]Hengge UR, GoosM, Esser S, et al. Randomized, controlled phase Ⅱ trial of subcutaneous interleukin-2 in combination with highly active antiretroviral treatment (HAART) in HIV patients[J]. AIDS,1998,12 (17):225-234.
[7]Tambussi G, Ghezzi S, Nozza S, et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL) 2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load:A controlled study of 3 IL-2 regimens with antiviral drug therapy[J]. J Infect Dis,2001,183 (10):1467-1484.
[8]王福生HIV/AIDS,患者免疫治疗和免疫重建研究进展[J].传染病信息,2005,18(4)：151-153.
[9]Kinloch-de Loes S. Role of therapeutic vaccines in the contol of HIV-1[J]. J Antimicrob Chemother,2004,53 (4):562-566.
[1]WHO/UNAIDS.AIDS epidemic update 2004. http://www.unaids.orgen.
[2]Wayne CK, Berkley SF. The renaissance in HIV vaccine development-future directions[J]. N Engl J Med;2010,363(5):e7.
[3]Kvitsinadze L, Tvildiani D, Pkhakadze G. Hiv/Aids prevalence in the southern caucasus[J]. Georgian Med News,2010,12(189):26-36.
[4]Jansen IA, Geskus RB, Davidovich U, Jurriaans S, et al. Ongoing HIV-1 transmission among men who have sex with men in Amsterdam:a 25-year prospective cohort study[J]. AIDS, 2011,25(4):493-501.
[5]Zhang YH, Bao YG, Sun JP, Tan HZ. Analysis of HIV/Syphilis/HCV infection among drug users in 15 cities, China[J]. Zhonghua Yu Fang Yi Xue Za Zhi,2010,44(11):969-974.
[6]Lei N, Peng ZH, Huan XP, et al. Estimation and prediction of the epidemic situation of acquired immunodeficiency syndrome in Jiangsu province[J]. Zhonghua Yu Fang Yi Xue Za Zhi,2010, 44(11):1012-1017.
[7]Jia M, Luo H, Ma Y, et al. The HIV epidemic in Yunnan Province, China,1989-2007[J]. J Acquir Immune Defic Syndr,2010,53(2):S34-40.
[8]Mildvan D, Mathur U, Enlow RW et al. Opportunistic infections and immune deficiency in homosexual men[J]. Ann Intern Med,1982,96(11):700-704.
[9]Vilcek J. Boosting p53 with interferon and viruses[J]. Nat Immunol,2003,4(8):825-826.
[10]Piacentini L, Biasin M, Fenizia C,et al. Genetic correlates of protection against HIV infection:the ally within[J]. J Intern Med,2008,265(1):110-124.
[11]Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection:know it, fix it, prevent it[J]? J Intern Med,2009,265(l):78-96.
[12]Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand[J].N Engl J Med,2009,361(23):2209-2220.
[13]Alcaro S, Alteri C, Artese A, et al. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase[J].Drug Resist Updat, 2011, Feb 2. [Epub ahead of print]
[14]Al-Mawsawi LQ, Neamati N. Allosteric Inhibitor Development Targeting HIV-1 Integrase[J].ChemMedChem,2011,6(2):228-241.
[15]Rhame FS. When to start antiretroviral therapy[J].Curr Infect Dis Rep,2011,13(1):60-67.
[16]Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease [J]. Lancet,1998, 351(9117):1682-1686.
[17]Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen[J]. AIDS,1999,13(6):669-676.
[18]Viard J, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in HIV-infected patients receiving HAART:evidence from the EuroSIDA study[J]. J Infect Dis,2001,183(8):1290-1294.
[19]Micheloud D, Berenguer J, Bellon JM, et al. Negative influence of age on CD4+cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency[J]. J Infect,2008,56(2):130-136.
[20]Kaufmann G, Bloch M, Finlayson R, et al. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy[J]. AIDS,2002, 16(3):359-367.
[21]Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy[J]. AIDS,2002,16(8):1139-1146.
[22]CDC.1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults[J]. MMWR Recomm Rep,1992,41(RR-17):1-19.
[23]Ramalingam S, Kannangai R, Abraham OC, et al. Investigation of apoptotic markers among human immunodeficiency virus (HIV-1) infected individuals[J]. Indian J Med Res,2008,128(12): 728-733.
[24]Wu NP, Li D, Bader A, et al. Effect of HIV-1 infection on apoptosis of CD4+ T lymphocytes mediated by Fas[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban,2003,32(2):90-93.
[25]Benveniste O, FlahauLt A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving HAART who have prolonged undetectable plasma viral loads[J]. J Infect Dis,2005,191(10):1670-1679.
[26]Isgro A, Mezzaroma I, Aiuti A, et al. Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during HAART[J]. AIDS,2004,18(9):1335-1337.
[27]Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts[J]. J Antimicrob Chemother,2004, 54(2)503-507.
[28]Khanna N, Opravil M, Furrer H, et al. CD4+T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy[J]. Clin Infect Dis,2009,47(8):1093-1101.
[29]Plana M, Martinez C, Garcia F, et al. Immunologic reconstitution after 1 year of HAART, with or without PI[J]. J Acquir Immune Defic Syndr,2002,29(5):429-434.
[30]Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfection:the Swiss HIV Cohort Study[J]. Lancet,2000,356(9244):1800-1805.
[31]Miller M, Haley C, Koziel M, et al. Impact of HCV on immune restoration in HIV-infected patients who start HAART:a meta-analysis[J]. Clin Infect Dis,2005,41(5):713-720.
[32]Peters L, Mocroft A, Soriano V, et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression[J]. J Acquir Immune Defic Syndr,2009,50(5):457-463.
[33]Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+T-cell response to HAART according to baseline CD4+T-cell count[J]. J Acquir Immune Defic Syndr,2004,36(2):702-713.
[34]Hunt P, Deeks S, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected aduLts experiencing 4 years of viral suppression on antiretroviral therapy[J]. AIDS,2003,17(13):1907-1915.
[35]Smith C, Sabin C, Lampe F, et al. The potential for CD4 cell increases in HIV-positive individuals who control viremia with HAART[J]. AIDS,2003,17(7):963-969.
[36]Hakim F, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery post-chemotherapy in aduLts: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells[J]. Blood,1997, 90(9)3789-3798.
[37]Isgro A, Mezzaroma I, Aiuti A, et al. Recovery of hematopoietic activity in bone marrow from HIV-1-infected patients during HAART[J]. AIDS Res Hum Retroviruses,2000,16(15):1471-1479.
[38]Card CM, McLaren PJ, Wachihi C, et al. Decreased Immune Activation in Resistance to HIV-1 Infection Is Associated with an Elevated Frequency of CD4+CD25+FOXP3+ ReguLatory T Cells[J]. J Infect Dis,2009,199(9):1318-1322.
[39]Kolte L, Gaardbo JC, Skogstrand K, et al. Increased levels of reguLatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs[J]. Clin Exp Immunol,2009,155(1):44-52.
[40]Teixeira L, Valdez H, McCune J, et al. Poor CD4 T-cell restoration after suppression of HIV-1 replication may reflect lower thymic function[J]. AIDS,2001,15(14):1749-1756.
[41]Antonella Isgro, Alessandro Aiuti, Wilma Leti, et al. Immunodysregulation of HIV disease at bone marrow level[J]. Autoimmun Rev,2005,4(8):486-490.
[42]Nasi M, Pinti M, Bugarini R, et al. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+T-cell count after antiretroviral therapy in drug-naive HIV-positive patients[J]. Immunogenetics,2005,57(9):628-635.
[43]Isgro A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART[J]. Clin Infect Dis,2008,46(12):1902-1910.
[44]Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate ongoing virus replication[J]. J Acquir Immune Defic Syndr,2004,35(1):33-37.
[45]Ostrowski S, Katzenstein T, Thim P, et al. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving HAART[J]. J Infect Dis,2005,191(1):348-357.
[46]马伯艳,符林春,蔡卫平,等.艾可清胶囊对高效抗病毒逆转录疗法的增效减毒作用[J].中国实验方剂学杂志,2007,13(8)：60-63.
[47]谢世平,潘万旗,郭会军,等.爱康胶囊对HIV/AIDS患者免疫功能影响的研究[J].辽宁中医杂志,2008,35(2)：165-167.
[48]危剑安,刘婧,宋春鑫,等.艾灵颗粒对HIV感染者CD4细胞和病毒载量的影响[J].河南中医学院学报,2008,23(3)：6-7.
[49]刘水腾,童新灯,黄华,等.活血培元法治疗对艾滋病患者T淋巴细胞功能的影响[J].井冈山学院学报(自然科学版),2006,27(4)：115-117.
[50]李发枝,徐立然,李柏龄等.中医药地173例艾滋病患者T淋巴细胞亚群的影响[J].中医杂志2006,47(1)：31-32.
[1]董振华.中医有关免疫学思维探讨[J].山西中医,1986,2(1)：40
[2]童瑶中医基础理论[M].北京：中国中医药报社,1999：153
[3]徐文玉.营养素与免疫和癌[J].上海免疫学杂志,1989,(3)：181
[4]张国山.中药及其临床[M].北京：中国医药科技出版社,1991：157,186
[5]金岚.新编中药药理与临床[M].上海：上海科学技术文献出版社,1995：79
[6]孙孝洪.补阴方药的研究近况[J].新医学,1980,11(3)：155
[7]张家庆.“阳虚”的临床和实验研究[J].中医杂志,1981,23(10)：37
[8]刘耕陶.冬虫夏草的免疫药理作用[J].中西医结合杂志,1985,5(10)：622。
[9周超凡.中医治则研究概况[J].中级医刊,1980,4(2)：25
[10]李凤云中药免疫功能的探讨[J].中医药研究,1995,6(3)：55
[11]吕维柏.艾滋病中西医防治学[M].北京：人民卫生出版社,1994.144.
[12]谢世平,潘万旗,梁慕华.艾滋病中医基本证型的相关文献分析[J].河南中医学院学报,2006,1(1)：6-8.
[13]黄剑雄,李峰,倪量.国内艾滋病中医文献的证候研究评价[J].辽宁中医杂志,2009,36(1)：1-3.
[14]赵晓梅.490例HIV感染者的流行病学及证候学分析[J].中国中医基础医学杂志,1995,1(4)：38.
[15]段呈玉,王莉,李艳萍,等.中医药治疗艾滋病与免疫重建炎性综合征相关性的研究初探[J].云南中医中药杂志,2008；29(5)：5-6.
[16]王健.55例HIV感染者死亡病例分析[J].中华流行病学杂志,1993；14(特刊)：160-161.
[17]李洪娟,李峰,王健,等.158例HIV/AIDS感染者常见中医症状和证候分析[J].北京中医药大学学报,2005,28(1)：69-72.
[18]杨凤珍,王健,赵敏,等.72例HIV/AIDS患者中医证候与T淋巴细胞亚群和病毒载量相关性研究[J].中国医药学报,2004,19(12)：733-737.
[19]邱红,谢世平,郭选贤HIV/AIDS患者274例中医证候流行病学分布[J].郑州大学学报(医学版),2007,42(2)：363-364.
[20]方路,王莉,段呈玉.云南省180例HIV/AIDS的中医症状及证候的初步分析[J].云南中医中药杂志,2006,27(3)：38-39.
[21]王融冰,王晓静,赵红心,等.艾滋病患者舌象分析与辨证[J].中医杂志,2006,47(4)：291-292.
[22]谢世平,潘万旗,许前磊.281例艾滋病患者常见中医证型与免疫指标相关性研究[J].中国中医基础医学杂志,2008,14(7)：520-521.
[23]岑玉文HIV/AIDS中医证型、证型演变及其与T淋巴细胞活化关系的研究.广州中医药大学博士论文,2008.
[24]王莉,段呈玉,瞿广城,等.艾滋病的中医证候和演变规律的研究概况[J].云南中医中药杂志,2008；29(2)：53-54.
[25]邹雯,王健.558例HIV/AIDS患者舌象分析及其与CD4+T淋巴细胞计数关系探讨[J].河南中医学院学报,2008,23(1)：7-11.
[26]邱红,谢世平,郭选贤.艾滋病的中医证候与辨证论治研究[J].河南中医学院学报,2005,9(5)：5-7.
[27]王树.在澳大利亚用中医药治疗艾滋病的体会和研讨[J].天津药学,2000,12(4)：1.
[28]谢世平.中医药治疗艾滋病研究思路[J].河南中医学院学报,2005,20(2)：1-3.
[29]Rinaldo C, Huang XL, Fan ZF, et al. High levels of antihuman immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors[J]. J Virol,1995,69(3):5838-5842.
[30]Betts MR, Exley B, Price DA, et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection [J]. Proc Natl Acad Sci USA,2005,102(11):4512-4517.
[31]Goudsmit J, Bogaards JA, Jurriaans, et al. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia[J]. AIDS,2002,16(12):791-793.
[32]汤艳莉,王阶.基因多态性与中医药防治艾滋病研究[J].北京中医药大学学报,2010,33(7)：444-446.
[33]Eggena MP, Barugahare B, Jones N et al. Depletion of regulatory T cells in HIV infection is associated with immune activation[J]. J Immunol,2005,174(3):4407-4414.
[34]Kinter A, McNally J, Riggin L, et al. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals[J]. Proc Natl Acad Sci USA,2007,104(7): 3390-3395.
[35]王阶,林洪生,汤艳莉.艾滋病免疫重建相关影响因素探讨[J].中国中西医结合杂志,2009,29(12)：1125-1129.
[36]王阶.中医药防治艾滋病的理论基础及其措施[J].中西医结合杂志1991,11(7)：430-432.
[37]黄剑雄,李峰,倪量艾滋病的中医病因病机研究[J].中医药学报,2009,37(2)：1-3.
[38]吕维柏.艾滋病中西医结合防治学[M].北京人民卫生出版社1994：172-177.
[39]汤艳莉,王阶艾滋病中医证候研究概况及思路[J].世界科学技术-中医药现代化,2009,11(5)：649-651.
[40]罗士德,范多青,王惠英,等.中草药抗艾滋病病毒活性研究[M]昆明：云南科学技术出版社,1998：6
[41]Xu HX, Wan M, Loh BN, et al. Screening of traditional medicaine for the irinhibitory activity against HIV-1 protease[J]. PhytotheraPy Research,1996,8(10):207-210
[42]关崇芬免疫干预疗法与中医药治疗艾滋病[J].中国中医基础医学杂志2004,10(5)：71-74
[43]马伯艳,符林春,陈谐捷,等.中药及中药复方制剂抗人类免疫缺陷病毒的研究进展[J].中医药信息,2007,24(2)：17-20
[44]关崇芬,王健,徐淑玲,等.中研2号治疗HIV/AIDS的临床和实验研究[J].中国中西医结合杂志,2003,23(7)：494.
[45]郭会军,刘学伟,王丹妮.扶正排毒Ⅰ号方治疗无症状HIV感染疗效观察[J].上海中医药杂志,2006,40(1)：20.
[46]彭勃,王丹妮.扶正排毒片Ⅱ号治疗无症状感染65例临床观察[J].中医药学刊,2006,24(10)：1781.
[47]Grazia Galli, Francesco Annunziato, Carmelo Mavilia, et al. Enhanced HIV expression during Th2-oriented responses explained by the opposite regulatory effect of IL-4 and IFN-γ on fusin/CXCR4[J]. Euro J Immunology.1998,28(10):3280-3290.
[48]汪习成,吴昊,李太生,等HIV/AIDS患者CD28在外周血CD4+、CD8+T细胞上的表达变化[J].中华微生物学和免疫学杂志2003,23(9)：700-702.
[49]汤艳莉,王阶.Toll样受体及其通路是中医药干预艾滋病免疫重建的可能作用靶点[J].中国中西医结合杂志,2010,30(6)：665-668.
[50]Raaphorst FM, Schelonka RL, Rusnak J, et al. CRBVCDR3 diversity of CD4 an d CD8 T-lymphocytes in HIV-infected individuals[J]. Hum Immunol,2002,63(1):51-60.
[51]Medzhitov R, Preston-Hurlburt P, Janeway CA Jr..A human homologue of the Drosophila Toll protein signals activation of adaptive immunity [J]. Nature,1997,388 (6640):394-397.
[52]Takeda K, Kaisho T,Akira S,et al. Toll-like receptors[J]. Annu Rev mmunol,2003,21(10):335-376.
[53]Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7,8 and 9 subfamily[J]. Eur J Immunol,2003,33 (11): 2987-2997.
[54]张群,雷林生,吴曙光.多糖类药物作用的受体及信号转导机制的研究进展[J].中草药,2005,36(4)：614-616.
[55]Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity[J]. Curr Opin Microbiol,2002,5(1):62-69.
[56]Schlaepfer E, Audige A, von Beust B, et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo[J] J Virol,2004,78 (22):12344-12354.
[57]AhmadNejad P, Hacker H, Rutz MP, et al. Bacterial CpG-DNA and lipoploysaccharides activate Toll-like receptors at distinct cellular compartments[J]. Eur J Immunol,2002,32(7):1958-1968.
[58]Sundstrum JB, Little DM, Villinqer F, et al. Singaling through Toll-like receptor triggers HIV-1 replication in latently infected mast cells [J]. Immunol,2004,172 (7):4391-4401.
[59]Field AK. Oligonucleotides as inhibitors of human immunodeficiency virus[J]. Curr Opin Mol Ther,1999,1(3) 323-331
[60]Beignon AS, McKenna K, Skobene M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions[J]. J Clin Invest,2005,115 (11):3265-3275.
[61]Equils O, Schito ML, Karahashih H,et al. Toll-Like Receptor 2 (TLR2) and TLR9 Signaling Results in HIV-Long Terminal Repeat Trans-Activation and HIV Replication in HIV-1 Transgenic Mouse Spleen Cells:Implications of Simultaneous Activation of TLRs on HIV Replication [J]. J Immunol,2003,170(10): 5159-5164.
[62]Mandl JN, Barry AP, Vanderford TH,et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections[J]. Nat Med. 2008,14(10):1077-1087.
[63]Anne-Sophie Beignon, Kelli McKenna, Mojca Skobeme, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions[J]. J. Clin. Invest.2005, 115(11):3265-3275.
[64]Scagnolari C, Selvaggi C, Chiavuzzo L, et.al. Expression Levels of TLRs Involved in Viral Recognition in PBMCs from HIV-1-Infected Patients Failing Antiretroviral Therapy[J]. Intervirology 2009,52:107-114
[65]周立平,尚红,王亚男,等.中国HIV/AIDS患者外周血单核细胞上TLR4表达和血浆TNF-α水平[J].中华微生物学和免疫学杂志.2007,27(11)：1016-1019.
[66]周立平,尚红韩晓旭等TLR4 mRNA在中国HIV/AIDS患者外周血单个核细胞中的表达及其与疾病进展关系的研究[J].中华检验医学杂志.2007,30(9)：1005-1008.
[67]曾星,王镓,蔡萃,等.TLR介导8CG和猪苓多糖激活巨噬细胞株J774 NF-κB的表达[J].免疫学杂志,2006,22(5)：515-518.
[68]彭煦,范晓静,石贤爱,等.香菇多糖对小鼠脾T/B淋巴细胞TLR4、TLR9表达的影响[J].中国临床药理学杂志2008,24(3)：234-236.
[69]李进,鲍依稀,祝绚,等.基因芯片研究云芝糖肽对健康成人外周血单个核细胞Toll样蛋白受体信号转导通路的影响[J].免疫学杂志,2008,24(2)：219-222.
[70]Shao BM, Dai H, Xu W, et al. Immune receptors for polysaccharides from Ganoderma lucidum [J].Biochem Biophys Res Commun,2004;323(1):133-141.
[71]Shao BM, Xu W, Dai H, et al. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus a Chinese medicinal herb[J]. Biochem Biophys Res Commun, 2004,320(4):1103-1111.
[72]Yoon YD, Han SB, Kang JS, et al. Toll-like receptor 4-dependent activation of macrophages by polysaccharide isolated from the radix of Platycodon grandiflorum [J]. Int Immunopharmacol,2003,3 (13-14):1873-1882.
[73]Han SB, Yoon YD, A hn HJ, et al. Toll-like receptor-mediated activation of B cells and macrophages by polysaccharide isolated from cell culture of Acanthopanax senticosus [J].J Immuno pharmacol,2003,3 (9):1301-1312.
[74]Ando I, T sukumo Y, Wakabayashi T, et al. Safflower polysaccharides activate the transcription factor NF-kappa B via Toll-like receptor 4 and induce cytokine production by macrophages [J]. Int Immuno pharmacol,2002,2 (8):1155-1162.
[75]赵丽芸,罗小星,陈镜合中药复苏饮对严重脓毒症患者外周血单核细胞TLR2、TLR4基因表达的影响[J].内蒙古中医药,2007,(5)：52-54.
[76]周婷,王青,周联,等.多种中药单体对人结肠癌HT-29细胞株TLR4 mRNA表达和IL-8分泌的影响[J].广州中医药大学学报,2007,24(2)：148-151.
[77]邝枣园,符林春,罗海燕,等.从受体角度探讨黄芩苷对肺炎衣原体感染细胞的干预机理[J].广州中医药大学学报,2005,22(3)：210-212
[78]徐世军,沈映君,金沈锐,等.桂枝挥发油干预LPS致大鼠急性肺炎模型肺Toll样受体2、4和MYD88基因表达的研究[J].成都中医药大学学报,2008,31(3)：32-37.
[79]赵保胜,李兰芳,马悦颖,等.参苏饮含药血清对小鼠巨噬细胞Toll样受体及其下游信号转 导通路的影响[J].中国中药杂志,2007,32(4)：327-332.
[80]赵保胜,刘洪斌,马悦颖,等.黄连解毒汤含药血清对Toll样受体34、型及其下游信号转导通路的影响[J].中国实验方剂学杂志2007,13(5)：15-20.
[81]赵保胜,刘洪斌,马悦颖,等.桂枝汤含药血清对小鼠巨噬细胞Toll样受体3、4型及其下游信号转导通路元件的影响[J].中药药理与临床2007,23(3)：1-4.
[82]Gay D,Saunders T, Camper S, et al. Receptor editing:an approach by autoreactive B cells to escape tolerance[J]. J Exp Med,1993,177(4):999-1008.
[83]Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells[J]. J Exp Med.1993,177(4):1009-1020.
[84]Assaf C, Hummel M, Dippel E,et al. High detection rate of T cell receptor beta chain rearrangements in T-cell lymphoproliferations by family specific polymerase chain reaction in combination with the Gene Scan technique and DNA sequencing [J]. Blood,2000,96(2):640-646.
[85]Prisco A, Bonomi G, Moschela F, et al. In vitro immunization with a recombinant antigen carrying the HIV-1 RT248-262 determinant inserted at diferent locations results in altered TCRVB region usage[J]. Hum Immunol,1999,60(9):755-763.
[86]Raaphorst FM, Schelonka RL, Rusnak J, et al. CRBVCDR3 diversity of CD4 an d CD8 T-lymphocytes in HIV-infected individuals[J]. Hum Immunol,2002,63(1):51-60.
[87]曹雪涛.免疫学前沿进展[M]北京：人民卫生出版社,2009：259.
[88]郭钦丽,王峰,沙文琼,等vMIP-Ⅱ对SIV感染的食蟹猴TCRVP基因表达的影响[J].免疫学杂志.2006,11(6)：604-607.
[1]Zhang M, Sun XD, Mark SD, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China[J]. Int J Epidemiol, 2003,33:1-7.
[2]Ball A. HIV, injecting drug use and harm reduction:a public health response[J]. Addiction,2007,102:684-690.
[3]Wu Z, Sullivan SG, Wang Y, et al. Evolution of China's response to HIV/AIDS[J]. Lancet,2007,369:679-690.
[4]Sullivan SG, Wu Z. Rapid scale up of harm reduction in China[J]. Int J Drug Policy,2006,18:118-128.41.
[5]Xinhuanet (2004) What is "Four Free, One Care"? (Available at http://news.xinhuanet.com/newscenter/2004-12/01/content_2281179.htm Accessed May 15,2010.)
[6]Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals[J]. Lancet,1997,349:1294.
[7]Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA,1998,27: 450-454.
[8]Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:comparison between low-income and high-income countries[J]. Lancet,2006,367:817-824.
[9]Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after Pl-containing antiretroviral regimen[J]. AIDS,1999, 13:669-676.
[10]Kaufmann D, Pantaleo G, Sudre P, et al. CD4-cell count in HIV-1-infected individuals remaining viremic with HAART. Swiss HIV Cohort Study[J]. Lancet, 1998,351:723-724.
[11]Yeni P, Hammer S, Hirsch M, et al. Treatment for Adult HIV Infection:2004. Recommendations of the International AIDS Society-USA Panel[J]. JAMA,2004, 292:251-65.
[12]Aiuti F, Mezzaroma I. Failure to Reconstitute CD4+ T-Cells Despite Suppression of HIV Replication under HAART[J]. AIDS Rev,2006,8:88-97.
[13]Kiboneka A, Nyatia RJ, Nabiryo C, et al. Combination antiretroviral therapy in population affected by conflict:outcomes from large cohort in northern Uganda[J]. BMJ,2009,338:b201.
[14]Cozzi-Lepri A, Phillips A, Clotet B, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study[J]. AIDS,2008,16:2187-2198.
[15]Jonathan A C, Miguel A, Bruno L, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death:a prospective cohort study. Lancet,2005,366:378-84.
[16]Lodwick RK, Sabin CA; Porter K, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America:a pooled cohort observational study. Lancet,2010, 376:340-345.
[17]Paul Leger, Macarthur Charles, Patrice Severe, et al.5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti[J]. N Engl J Med,2009, 20:828-829.
[18]Robert S Hogg, Benita Yip, Keith J Chan, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy[J]. JAMA, 2001,286:2560-97.
[19]Jose Ricardo P. Marins, Leda F. Jamal, et al. Dramatic improvement in survival among adult Brazilian AIDS patients[J]. AIDS,2003,17:1675-1682.
[1]Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy:the new challenge in HIV-1 infection[J]. Blood,2011,117(21):5582-5590.
[2]Centers for Disease Control and Prevention.1993 revised classification system for H IV infection and expanded surveillance case definition for A IDS among adolescents and adults [S]. MMWR Recomm Rep,1992,41 (RR217):1.
[3]李发枝,徐立然,李柏龄,等.中医药对173例艾滋病患者T淋巴细胞亚群的影 响[J].中医杂志,2006,47(1)：31-32.
[4]马伯艳,符林春,蔡卫平,等.艾可清胶囊对高效抗病毒逆转录疗法的增效减毒作用[J].中国实验方剂学杂志,2007,13(8)：60-63.
[5]谢世平,潘万旗,郭会军,等.爱康胶囊对HIV/AIDS,患者免疫功能影响的研究[J].辽宁中医杂志,2008,35(2)：165-167.
[6]李太生,Carcelaine G,Debre P,等.高效抗病毒治疗促使艾滋病患者免疫功能重建[J].基础医学与临床,2001,21(1)：6211.
[7]Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads [J]. J Infect Dis,2005,191(10):1670-1679.
[8]Marziali M, De Santis W, Carello R, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART[J]. AIDS,2006,20(16):2033-2041.
[9]Isgro A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART [J]. Clin Infect Dis,2008, 46(12):1902-1910.
[10]Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy [J]. J Infect Dis,2000, 181(1):141-147.
[11]Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen [J]. AIDS, 1999,13(6):669-676.
[12]FDA. Guidance for industry-patient-reported outcome measures:use in medical product development to support labeling claims, draft guidance. Health Qual Life,2006,4:79.
[13]王艳宏,刘中申,关枫,等.西洋参及其制剂的免疫调节作用研究[J].中医药学刊,2004,22(3)：566-567.
[14]张娴,力曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(1)：20-22.
[15]郭宏春,高继全,习欠云,等.冬虫夏草研究进展[J].微生物学杂志,2003,23(1)：50-55.
[16]Prisco A, Bonomi G, Moschela F, et al. In vitro immunization with a recombinant antigen carrying the HIV-1 RT248-262 determinant inserted at diferent locations results in altered TCRVB region usage[J]. Hum Immunol,1999, 60(9):755-763.
[17]Raaphorst FM, Schelonka RL, RusnakJ, et al. CRVBCDR3 diversity of CD4 an d CD8 T-lymphocytes in HIV-infected individuals[J]. Hum Immunol,2002, 63(1):51-60.
[18]Jamie D.K. Wilson, Graham S. Ogg, Rachel L. Allen. Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific[J]. JEM,1998,188(4): 785-790
[19]S. Ramzaoui,F.Jouen-beades,F.Michot,et al.Comparison of activation marker and TCR Vβ gene product expression by CD4+ and CD8+ T cells in peripheral blood and lymph nodes from HIV-infected patients[J]. Clinical & Experimental Immunology,2008,99(2):182-188.
[20]Mark Connors, Joseph A. Kovacs, Seth Krevat, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Medicine,1997,60(3):533-540.
[21]M.Roglic, R.D.Macphee,S.R. Duncan,et al. T cell receptor (TCR) BV gene repertoires and clonal expansions of CD4 cells in patients with HIV infections[J]. Clinical & Experimental Immunology,2003,107(1):21-30.
[22]Li Yin, Zhong Chen Kou, Carina Rodriguez, et al. Antiretroviral Therapy Restores Diversity in the T-Cell Receptor vβ Repertoire of CD4 T-Cell Subpopulations among Human Immunodeficiency Virus Type 1-Infected Children and Adolescents[J]. Clinical and Vaccine Immunology,2009,16(9):1293-1301.
[23]Hongbing Yang, Tao Dong, Emma Turnbull, et al.Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy[J]. The Journal of Immunology,2007, 17(9):597-606.
[24]Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity [J]. Nature,1997, 388 (6640):394-397.
[25]汤艳莉,王阶.Toll样受体及其通路是中医药干预艾滋病免疫重建的可能作用靶点[J].中国中西医结合杂志,2010,30(6)：665-668.
[26]Kanehisa M, Goto S:KEGG:Kyoto Encyclopedia of Genes and Genomes[J]. Nucleic Acids Res,2000,28(1):27-30.
[27]Wagner H, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity[J]. Curr Opin Microbiol,2002,5(1):62-69.
[28]Schlaepfer E, Audige A, von Beust B, et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo[J]. J Virol,2004,78 (22):12344-12354.
[29]AhmadNejad P, Hacker H, Rutz MP, et al. Bacterial CpG-DNA and lipoploysaccharides activate Toll-like receptors at distinct cellular compartments[J]. Eur J Immunol,2002,32(7):1958-1968.
[30]Scagnolari C, Selvaggi C, Chiavuzzo L, et al. Expression Levels of TLRs Involved in Viral Recognition in PBMCs from HIV-1-Infected Patients Failing Antiretroviral Therapy [J]. Intervirology,2009,52:107-114.
[31]汤艳莉,王阶.“以平为期”理念在艾滋病免疫失调调节中的应用[J].2011,26(5)：915-918.
[32]彭广华,贺新怀,席孝贤,等.从Toll样受体探讨中药抗感染免疫作用机制[J].2006,24(11)：2084-2085.
[33]Uciechowski P, Imhoff H,Lange C, et al. Susceptibility to tuberculosis is associated with TLR1 polymorphisms resulting in a lack of TLR1 cell surface expression[J]. J Leukoc Biol,2011,90(2):377-88.
[2]李扬秋.T细胞受体的研究和应用[M].人民卫生出版社,2009.1：122.
[3]林文棠.临床免疫学[M].第四军医大学出版社,2002.7：339.
[4]Hiitter q Nowak D, Mossner M, et al. Long-term control of HIV by CCRS Delta32/Delta32 stemcell transplantation[J]. N Engl J Med,2009,360(7):724-725.
[5]Imami N, Gotch F. Prospects for immune reconstitution in HTV-1 infection[J]. Clin Exp Immunol, 2002,127 (3):402-411.
[6]Hengge UR, GoosM, Esser S, et al. Randomized, controlled phase Ⅱ trial of subcutaneous interleukin-2 in combination with highly active antiretroviral treatment (HAART) in HIV patients[J]. AIDS,1998,12 (17):225-234.
[7]Tambussi G, Ghezzi S, Nozza S, et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL) 2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load:A controlled study of 3 IL-2 regimens with antiviral drug therapy[J]. J Infect Dis,2001,183 (10):1467-1484.
[8]王福生HIV/AIDS,患者免疫治疗和免疫重建研究进展[J].传染病信息,2005,18(4)：151-153.
[9]Kinloch-de Loes S. Role of therapeutic vaccines in the contol of HIV-1[J]. J Antimicrob Chemother,2004,53 (4):562-566.
[1]WHO/UNAIDS.AIDS epidemic update 2004. http://www.unaids.orgen.
[2]Wayne CK, Berkley SF. The renaissance in HIV vaccine development-future directions[J]. N Engl J Med;2010,363(5):e7.
[3]Kvitsinadze L, Tvildiani D, Pkhakadze G. Hiv/Aids prevalence in the southern caucasus[J]. Georgian Med News,2010,12(189):26-36.
[4]Jansen IA, Geskus RB, Davidovich U, Jurriaans S, et al. Ongoing HIV-1 transmission among men who have sex with men in Amsterdam:a 25-year prospective cohort study[J]. AIDS, 2011,25(4):493-501.
[5]Zhang YH, Bao YG, Sun JP, Tan HZ. Analysis of HIV/Syphilis/HCV infection among drug users in 15 cities, China[J]. Zhonghua Yu Fang Yi Xue Za Zhi,2010,44(11):969-974.
[6]Lei N, Peng ZH, Huan XP, et al. Estimation and prediction of the epidemic situation of acquired immunodeficiency syndrome in Jiangsu province[J]. Zhonghua Yu Fang Yi Xue Za Zhi,2010, 44(11):1012-1017.
[7]Jia M, Luo H, Ma Y, et al. The HIV epidemic in Yunnan Province, China,1989-2007[J]. J Acquir Immune Defic Syndr,2010,53(2):S34-40.
[8]Mildvan D, Mathur U, Enlow RW et al. Opportunistic infections and immune deficiency in homosexual men[J]. Ann Intern Med,1982,96(11):700-704.
[9]Vilcek J. Boosting p53 with interferon and viruses[J]. Nat Immunol,2003,4(8):825-826.
[10]Piacentini L, Biasin M, Fenizia C,et al. Genetic correlates of protection against HIV infection:the ally within[J]. J Intern Med,2008,265(1):110-124.
[11]Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection:know it, fix it, prevent it[J]? J Intern Med,2009,265(l):78-96.
[12]Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand[J].N Engl J Med,2009,361(23):2209-2220.
[13]Alcaro S, Alteri C, Artese A, et al. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase[J].Drug Resist Updat, 2011, Feb 2. [Epub ahead of print]
[14]Al-Mawsawi LQ, Neamati N. Allosteric Inhibitor Development Targeting HIV-1 Integrase[J].ChemMedChem,2011,6(2):228-241.
[15]Rhame FS. When to start antiretroviral therapy[J].Curr Infect Dis Rep,2011,13(1):60-67.
[16]Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease [J]. Lancet,1998, 351(9117):1682-1686.
[17]Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen[J]. AIDS,1999,13(6):669-676.
[18]Viard J, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in HIV-infected patients receiving HAART:evidence from the EuroSIDA study[J]. J Infect Dis,2001,183(8):1290-1294.
[19]Micheloud D, Berenguer J, Bellon JM, et al. Negative influence of age on CD4+cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency[J]. J Infect,2008,56(2):130-136.
[20]Kaufmann G, Bloch M, Finlayson R, et al. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy[J]. AIDS,2002, 16(3):359-367.
[21]Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy[J]. AIDS,2002,16(8):1139-1146.
[22]CDC.1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults[J]. MMWR Recomm Rep,1992,41(RR-17):1-19.
[23]Ramalingam S, Kannangai R, Abraham OC, et al. Investigation of apoptotic markers among human immunodeficiency virus (HIV-1) infected individuals[J]. Indian J Med Res,2008,128(12): 728-733.
[24]Wu NP, Li D, Bader A, et al. Effect of HIV-1 infection on apoptosis of CD4+ T lymphocytes mediated by Fas[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban,2003,32(2):90-93.
[25]Benveniste O, FlahauLt A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving HAART who have prolonged undetectable plasma viral loads[J]. J Infect Dis,2005,191(10):1670-1679.
[26]Isgro A, Mezzaroma I, Aiuti A, et al. Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during HAART[J]. AIDS,2004,18(9):1335-1337.
[27]Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts[J]. J Antimicrob Chemother,2004, 54(2)503-507.
[28]Khanna N, Opravil M, Furrer H, et al. CD4+T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy[J]. Clin Infect Dis,2009,47(8):1093-1101.
[29]Plana M, Martinez C, Garcia F, et al. Immunologic reconstitution after 1 year of HAART, with or without PI[J]. J Acquir Immune Defic Syndr,2002,29(5):429-434.
[30]Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfection:the Swiss HIV Cohort Study[J]. Lancet,2000,356(9244):1800-1805.
[31]Miller M, Haley C, Koziel M, et al. Impact of HCV on immune restoration in HIV-infected patients who start HAART:a meta-analysis[J]. Clin Infect Dis,2005,41(5):713-720.
[32]Peters L, Mocroft A, Soriano V, et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression[J]. J Acquir Immune Defic Syndr,2009,50(5):457-463.
[33]Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+T-cell response to HAART according to baseline CD4+T-cell count[J]. J Acquir Immune Defic Syndr,2004,36(2):702-713.
[34]Hunt P, Deeks S, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected aduLts experiencing 4 years of viral suppression on antiretroviral therapy[J]. AIDS,2003,17(13):1907-1915.
[35]Smith C, Sabin C, Lampe F, et al. The potential for CD4 cell increases in HIV-positive individuals who control viremia with HAART[J]. AIDS,2003,17(7):963-969.
[36]Hakim F, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery post-chemotherapy in aduLts: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells[J]. Blood,1997, 90(9)3789-3798.
[37]Isgro A, Mezzaroma I, Aiuti A, et al. Recovery of hematopoietic activity in bone marrow from HIV-1-infected patients during HAART[J]. AIDS Res Hum Retroviruses,2000,16(15):1471-1479.
[38]Card CM, McLaren PJ, Wachihi C, et al. Decreased Immune Activation in Resistance to HIV-1 Infection Is Associated with an Elevated Frequency of CD4+CD25+FOXP3+ ReguLatory T Cells[J]. J Infect Dis,2009,199(9):1318-1322.
[39]Kolte L, Gaardbo JC, Skogstrand K, et al. Increased levels of reguLatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs[J]. Clin Exp Immunol,2009,155(1):44-52.
[40]Teixeira L, Valdez H, McCune J, et al. Poor CD4 T-cell restoration after suppression of HIV-1 replication may reflect lower thymic function[J]. AIDS,2001,15(14):1749-1756.
[41]Antonella Isgro, Alessandro Aiuti, Wilma Leti, et al. Immunodysregulation of HIV disease at bone marrow level[J]. Autoimmun Rev,2005,4(8):486-490.
[42]Nasi M, Pinti M, Bugarini R, et al. Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+T-cell count after antiretroviral therapy in drug-naive HIV-positive patients[J]. Immunogenetics,2005,57(9):628-635.
[43]Isgro A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART[J]. Clin Infect Dis,2008,46(12):1902-1910.
[44]Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate ongoing virus replication[J]. J Acquir Immune Defic Syndr,2004,35(1):33-37.
[45]Ostrowski S, Katzenstein T, Thim P, et al. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving HAART[J]. J Infect Dis,2005,191(1):348-357.
[46]马伯艳,符林春,蔡卫平,等.艾可清胶囊对高效抗病毒逆转录疗法的增效减毒作用[J].中国实验方剂学杂志,2007,13(8)：60-63.
[47]谢世平,潘万旗,郭会军,等.爱康胶囊对HIV/AIDS患者免疫功能影响的研究[J].辽宁中医杂志,2008,35(2)：165-167.
[48]危剑安,刘婧,宋春鑫,等.艾灵颗粒对HIV感染者CD4细胞和病毒载量的影响[J].河南中医学院学报,2008,23(3)：6-7.
[49]刘水腾,童新灯,黄华,等.活血培元法治疗对艾滋病患者T淋巴细胞功能的影响[J].井冈山学院学报(自然科学版),2006,27(4)：115-117.
[50]李发枝,徐立然,李柏龄等.中医药地173例艾滋病患者T淋巴细胞亚群的影响[J].中医杂志2006,47(1)：31-32.
[1]董振华.中医有关免疫学思维探讨[J].山西中医,1986,2(1)：40
[2]童瑶中医基础理论[M].北京：中国中医药报社,1999：153
[3]徐文玉.营养素与免疫和癌[J].上海免疫学杂志,1989,(3)：181
[4]张国山.中药及其临床[M].北京：中国医药科技出版社,1991：157,186
[5]金岚.新编中药药理与临床[M].上海：上海科学技术文献出版社,1995：79
[6]孙孝洪.补阴方药的研究近况[J].新医学,1980,11(3)：155
[7]张家庆.“阳虚”的临床和实验研究[J].中医杂志,1981,23(10)：37
[8]刘耕陶.冬虫夏草的免疫药理作用[J].中西医结合杂志,1985,5(10)：622。
[9周超凡.中医治则研究概况[J].中级医刊,1980,4(2)：25
[10]李凤云中药免疫功能的探讨[J].中医药研究,1995,6(3)：55
[11]吕维柏.艾滋病中西医防治学[M].北京：人民卫生出版社,1994.144.
[12]谢世平,潘万旗,梁慕华.艾滋病中医基本证型的相关文献分析[J].河南中医学院学报,2006,1(1)：6-8.
[13]黄剑雄,李峰,倪量.国内艾滋病中医文献的证候研究评价[J].辽宁中医杂志,2009,36(1)：1-3.
[14]赵晓梅.490例HIV感染者的流行病学及证候学分析[J].中国中医基础医学杂志,1995,1(4)：38.
[15]段呈玉,王莉,李艳萍,等.中医药治疗艾滋病与免疫重建炎性综合征相关性的研究初探[J].云南中医中药杂志,2008；29(5)：5-6.
[16]王健.55例HIV感染者死亡病例分析[J].中华流行病学杂志,1993；14(特刊)：160-161.
[17]李洪娟,李峰,王健,等.158例HIV/AIDS感染者常见中医症状和证候分析[J].北京中医药大学学报,2005,28(1)：69-72.
[18]杨凤珍,王健,赵敏,等.72例HIV/AIDS患者中医证候与T淋巴细胞亚群和病毒载量相关性研究[J].中国医药学报,2004,19(12)：733-737.
[19]邱红,谢世平,郭选贤HIV/AIDS患者274例中医证候流行病学分布[J].郑州大学学报(医学版),2007,42(2)：363-364.
[20]方路,王莉,段呈玉.云南省180例HIV/AIDS的中医症状及证候的初步分析[J].云南中医中药杂志,2006,27(3)：38-39.
[21]王融冰,王晓静,赵红心,等.艾滋病患者舌象分析与辨证[J].中医杂志,2006,47(4)：291-292.
[22]谢世平,潘万旗,许前磊.281例艾滋病患者常见中医证型与免疫指标相关性研究[J].中国中医基础医学杂志,2008,14(7)：520-521.
[23]岑玉文HIV/AIDS中医证型、证型演变及其与T淋巴细胞活化关系的研究.广州中医药大学博士论文,2008.
[24]王莉,段呈玉,瞿广城,等.艾滋病的中医证候和演变规律的研究概况[J].云南中医中药杂志,2008；29(2)：53-54.
[25]邹雯,王健.558例HIV/AIDS患者舌象分析及其与CD4+T淋巴细胞计数关系探讨[J].河南中医学院学报,2008,23(1)：7-11.
[26]邱红,谢世平,郭选贤.艾滋病的中医证候与辨证论治研究[J].河南中医学院学报,2005,9(5)：5-7.
[27]王树.在澳大利亚用中医药治疗艾滋病的体会和研讨[J].天津药学,2000,12(4)：1.
[28]谢世平.中医药治疗艾滋病研究思路[J].河南中医学院学报,2005,20(2)：1-3.
[29]Rinaldo C, Huang XL, Fan ZF, et al. High levels of antihuman immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors[J]. J Virol,1995,69(3):5838-5842.
[30]Betts MR, Exley B, Price DA, et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection [J]. Proc Natl Acad Sci USA,2005,102(11):4512-4517.
[31]Goudsmit J, Bogaards JA, Jurriaans, et al. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia[J]. AIDS,2002,16(12):791-793.
[32]汤艳莉,王阶.基因多态性与中医药防治艾滋病研究[J].北京中医药大学学报,2010,33(7)：444-446.
[33]Eggena MP, Barugahare B, Jones N et al. Depletion of regulatory T cells in HIV infection is associated with immune activation[J]. J Immunol,2005,174(3):4407-4414.
[34]Kinter A, McNally J, Riggin L, et al. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals[J]. Proc Natl Acad Sci USA,2007,104(7): 3390-3395.
[35]王阶,林洪生,汤艳莉.艾滋病免疫重建相关影响因素探讨[J].中国中西医结合杂志,2009,29(12)：1125-1129.
[36]王阶.中医药防治艾滋病的理论基础及其措施[J].中西医结合杂志1991,11(7)：430-432.
[37]黄剑雄,李峰,倪量艾滋病的中医病因病机研究[J].中医药学报,2009,37(2)：1-3.
[38]吕维柏.艾滋病中西医结合防治学[M].北京人民卫生出版社1994：172-177.
[39]汤艳莉,王阶艾滋病中医证候研究概况及思路[J].世界科学技术-中医药现代化,2009,11(5)：649-651.
[40]罗士德,范多青,王惠英,等.中草药抗艾滋病病毒活性研究[M]昆明：云南科学技术出版社,1998：6
[41]Xu HX, Wan M, Loh BN, et al. Screening of traditional medicaine for the irinhibitory activity against HIV-1 protease[J]. PhytotheraPy Research,1996,8(10):207-210
[42]关崇芬免疫干预疗法与中医药治疗艾滋病[J].中国中医基础医学杂志2004,10(5)：71-74
[43]马伯艳,符林春,陈谐捷,等.中药及中药复方制剂抗人类免疫缺陷病毒的研究进展[J].中医药信息,2007,24(2)：17-20
[44]关崇芬,王健,徐淑玲,等.中研2号治疗HIV/AIDS的临床和实验研究[J].中国中西医结合杂志,2003,23(7)：494.
[45]郭会军,刘学伟,王丹妮.扶正排毒Ⅰ号方治疗无症状HIV感染疗效观察[J].上海中医药杂志,2006,40(1)：20.
[46]彭勃,王丹妮.扶正排毒片Ⅱ号治疗无症状感染65例临床观察[J].中医药学刊,2006,24(10)：1781.
[47]Grazia Galli, Francesco Annunziato, Carmelo Mavilia, et al. Enhanced HIV expression during Th2-oriented responses explained by the opposite regulatory effect of IL-4 and IFN-γ on fusin/CXCR4[J]. Euro J Immunology.1998,28(10):3280-3290.
[48]汪习成,吴昊,李太生,等HIV/AIDS患者CD28在外周血CD4+、CD8+T细胞上的表达变化[J].中华微生物学和免疫学杂志2003,23(9)：700-702.
[49]汤艳莉,王阶.Toll样受体及其通路是中医药干预艾滋病免疫重建的可能作用靶点[J].中国中西医结合杂志,2010,30(6)：665-668.
[50]Raaphorst FM, Schelonka RL, Rusnak J, et al. CRBVCDR3 diversity of CD4 an d CD8 T-lymphocytes in HIV-infected individuals[J]. Hum Immunol,2002,63(1):51-60.
[51]Medzhitov R, Preston-Hurlburt P, Janeway CA Jr..A human homologue of the Drosophila Toll protein signals activation of adaptive immunity [J]. Nature,1997,388 (6640):394-397.
[52]Takeda K, Kaisho T,Akira S,et al. Toll-like receptors[J]. Annu Rev mmunol,2003,21(10):335-376.
[53]Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7,8 and 9 subfamily[J]. Eur J Immunol,2003,33 (11): 2987-2997.
[54]张群,雷林生,吴曙光.多糖类药物作用的受体及信号转导机制的研究进展[J].中草药,2005,36(4)：614-616.
[55]Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity[J]. Curr Opin Microbiol,2002,5(1):62-69.
[56]Schlaepfer E, Audige A, von Beust B, et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo[J] J Virol,2004,78 (22):12344-12354.
[57]AhmadNejad P, Hacker H, Rutz MP, et al. Bacterial CpG-DNA and lipoploysaccharides activate Toll-like receptors at distinct cellular compartments[J]. Eur J Immunol,2002,32(7):1958-1968.
[58]Sundstrum JB, Little DM, Villinqer F, et al. Singaling through Toll-like receptor triggers HIV-1 replication in latently infected mast cells [J]. Immunol,2004,172 (7):4391-4401.
[59]Field AK. Oligonucleotides as inhibitors of human immunodeficiency virus[J]. Curr Opin Mol Ther,1999,1(3) 323-331
[60]Beignon AS, McKenna K, Skobene M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions[J]. J Clin Invest,2005,115 (11):3265-3275.
[61]Equils O, Schito ML, Karahashih H,et al. Toll-Like Receptor 2 (TLR2) and TLR9 Signaling Results in HIV-Long Terminal Repeat Trans-Activation and HIV Replication in HIV-1 Transgenic Mouse Spleen Cells:Implications of Simultaneous Activation of TLRs on HIV Replication [J]. J Immunol,2003,170(10): 5159-5164.
[62]Mandl JN, Barry AP, Vanderford TH,et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections[J]. Nat Med. 2008,14(10):1077-1087.
[63]Anne-Sophie Beignon, Kelli McKenna, Mojca Skobeme, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions[J]. J. Clin. Invest.2005, 115(11):3265-3275.
[64]Scagnolari C, Selvaggi C, Chiavuzzo L, et.al. Expression Levels of TLRs Involved in Viral Recognition in PBMCs from HIV-1-Infected Patients Failing Antiretroviral Therapy[J]. Intervirology 2009,52:107-114
[65]周立平,尚红,王亚男,等.中国HIV/AIDS患者外周血单核细胞上TLR4表达和血浆TNF-α水平[J].中华微生物学和免疫学杂志.2007,27(11)：1016-1019.
[66]周立平,尚红韩晓旭等TLR4 mRNA在中国HIV/AIDS患者外周血单个核细胞中的表达及其与疾病进展关系的研究[J].中华检验医学杂志.2007,30(9)：1005-1008.
[67]曾星,王镓,蔡萃,等.TLR介导8CG和猪苓多糖激活巨噬细胞株J774 NF-κB的表达[J].免疫学杂志,2006,22(5)：515-518.
[68]彭煦,范晓静,石贤爱,等.香菇多糖对小鼠脾T/B淋巴细胞TLR4、TLR9表达的影响[J].中国临床药理学杂志2008,24(3)：234-236.
[69]李进,鲍依稀,祝绚,等.基因芯片研究云芝糖肽对健康成人外周血单个核细胞Toll样蛋白受体信号转导通路的影响[J].免疫学杂志,2008,24(2)：219-222.
[70]Shao BM, Dai H, Xu W, et al. Immune receptors for polysaccharides from Ganoderma lucidum [J].Biochem Biophys Res Commun,2004;323(1):133-141.
[71]Shao BM, Xu W, Dai H, et al. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus a Chinese medicinal herb[J]. Biochem Biophys Res Commun, 2004,320(4):1103-1111.
[72]Yoon YD, Han SB, Kang JS, et al. Toll-like receptor 4-dependent activation of macrophages by polysaccharide isolated from the radix of Platycodon grandiflorum [J]. Int Immunopharmacol,2003,3 (13-14):1873-1882.
[73]Han SB, Yoon YD, A hn HJ, et al. Toll-like receptor-mediated activation of B cells and macrophages by polysaccharide isolated from cell culture of Acanthopanax senticosus [J].J Immuno pharmacol,2003,3 (9):1301-1312.
[74]Ando I, T sukumo Y, Wakabayashi T, et al. Safflower polysaccharides activate the transcription factor NF-kappa B via Toll-like receptor 4 and induce cytokine production by macrophages [J]. Int Immuno pharmacol,2002,2 (8):1155-1162.
[75]赵丽芸,罗小星,陈镜合中药复苏饮对严重脓毒症患者外周血单核细胞TLR2、TLR4基因表达的影响[J].内蒙古中医药,2007,(5)：52-54.
[76]周婷,王青,周联,等.多种中药单体对人结肠癌HT-29细胞株TLR4 mRNA表达和IL-8分泌的影响[J].广州中医药大学学报,2007,24(2)：148-151.
[77]邝枣园,符林春,罗海燕,等.从受体角度探讨黄芩苷对肺炎衣原体感染细胞的干预机理[J].广州中医药大学学报,2005,22(3)：210-212
[78]徐世军,沈映君,金沈锐,等.桂枝挥发油干预LPS致大鼠急性肺炎模型肺Toll样受体2、4和MYD88基因表达的研究[J].成都中医药大学学报,2008,31(3)：32-37.
[79]赵保胜,李兰芳,马悦颖,等.参苏饮含药血清对小鼠巨噬细胞Toll样受体及其下游信号转 导通路的影响[J].中国中药杂志,2007,32(4)：327-332.
[80]赵保胜,刘洪斌,马悦颖,等.黄连解毒汤含药血清对Toll样受体34、型及其下游信号转导通路的影响[J].中国实验方剂学杂志2007,13(5)：15-20.
[81]赵保胜,刘洪斌,马悦颖,等.桂枝汤含药血清对小鼠巨噬细胞Toll样受体3、4型及其下游信号转导通路元件的影响[J].中药药理与临床2007,23(3)：1-4.
[82]Gay D,Saunders T, Camper S, et al. Receptor editing:an approach by autoreactive B cells to escape tolerance[J]. J Exp Med,1993,177(4):999-1008.
[83]Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells[J]. J Exp Med.1993,177(4):1009-1020.
[84]Assaf C, Hummel M, Dippel E,et al. High detection rate of T cell receptor beta chain rearrangements in T-cell lymphoproliferations by family specific polymerase chain reaction in combination with the Gene Scan technique and DNA sequencing [J]. Blood,2000,96(2):640-646.
[85]Prisco A, Bonomi G, Moschela F, et al. In vitro immunization with a recombinant antigen carrying the HIV-1 RT248-262 determinant inserted at diferent locations results in altered TCRVB region usage[J]. Hum Immunol,1999,60(9):755-763.
[86]Raaphorst FM, Schelonka RL, Rusnak J, et al. CRBVCDR3 diversity of CD4 an d CD8 T-lymphocytes in HIV-infected individuals[J]. Hum Immunol,2002,63(1):51-60.
[87]曹雪涛.免疫学前沿进展[M]北京：人民卫生出版社,2009：259.
[88]郭钦丽,王峰,沙文琼,等vMIP-Ⅱ对SIV感染的食蟹猴TCRVP基因表达的影响[J].免疫学杂志.2006,11(6)：604-607.
[1]Zhang M, Sun XD, Mark SD, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China[J]. Int J Epidemiol, 2003,33:1-7.
[2]Ball A. HIV, injecting drug use and harm reduction:a public health response[J]. Addiction,2007,102:684-690.
[3]Wu Z, Sullivan SG, Wang Y, et al. Evolution of China's response to HIV/AIDS[J]. Lancet,2007,369:679-690.
[4]Sullivan SG, Wu Z. Rapid scale up of harm reduction in China[J]. Int J Drug Policy,2006,18:118-128.41.
[5]Xinhuanet (2004) What is "Four Free, One Care"? (Available at http://news.xinhuanet.com/newscenter/2004-12/01/content_2281179.htm Accessed May 15,2010.)
[6]Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals[J]. Lancet,1997,349:1294.
[7]Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA,1998,27: 450-454.
[8]Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy:comparison between low-income and high-income countries[J]. Lancet,2006,367:817-824.
[9]Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after Pl-containing antiretroviral regimen[J]. AIDS,1999, 13:669-676.
[10]Kaufmann D, Pantaleo G, Sudre P, et al. CD4-cell count in HIV-1-infected individuals remaining viremic with HAART. Swiss HIV Cohort Study[J]. Lancet, 1998,351:723-724.
[11]Yeni P, Hammer S, Hirsch M, et al. Treatment for Adult HIV Infection:2004. Recommendations of the International AIDS Society-USA Panel[J]. JAMA,2004, 292:251-65.
[12]Aiuti F, Mezzaroma I. Failure to Reconstitute CD4+ T-Cells Despite Suppression of HIV Replication under HAART[J]. AIDS Rev,2006,8:88-97.
[13]Kiboneka A, Nyatia RJ, Nabiryo C, et al. Combination antiretroviral therapy in population affected by conflict:outcomes from large cohort in northern Uganda[J]. BMJ,2009,338:b201.
[14]Cozzi-Lepri A, Phillips A, Clotet B, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study[J]. AIDS,2008,16:2187-2198.
[15]Jonathan A C, Miguel A, Bruno L, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death:a prospective cohort study. Lancet,2005,366:378-84.
[16]Lodwick RK, Sabin CA; Porter K, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America:a pooled cohort observational study. Lancet,2010, 376:340-345.
[17]Paul Leger, Macarthur Charles, Patrice Severe, et al.5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti[J]. N Engl J Med,2009, 20:828-829.
[18]Robert S Hogg, Benita Yip, Keith J Chan, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy[J]. JAMA, 2001,286:2560-97.
[19]Jose Ricardo P. Marins, Leda F. Jamal, et al. Dramatic improvement in survival among adult Brazilian AIDS patients[J]. AIDS,2003,17:1675-1682.
[1]Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy:the new challenge in HIV-1 infection[J]. Blood,2011,117(21):5582-5590.
[2]Centers for Disease Control and Prevention.1993 revised classification system for H IV infection and expanded surveillance case definition for A IDS among adolescents and adults [S]. MMWR Recomm Rep,1992,41 (RR217):1.
[3]李发枝,徐立然,李柏龄,等.中医药对173例艾滋病患者T淋巴细胞亚群的影 响[J].中医杂志,2006,47(1)：31-32.
[4]马伯艳,符林春,蔡卫平,等.艾可清胶囊对高效抗病毒逆转录疗法的增效减毒作用[J].中国实验方剂学杂志,2007,13(8)：60-63.
[5]谢世平,潘万旗,郭会军,等.爱康胶囊对HIV/AIDS,患者免疫功能影响的研究[J].辽宁中医杂志,2008,35(2)：165-167.
[6]李太生,Carcelaine G,Debre P,等.高效抗病毒治疗促使艾滋病患者免疫功能重建[J].基础医学与临床,2001,21(1)：6211.
[7]Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads [J]. J Infect Dis,2005,191(10):1670-1679.
[8]Marziali M, De Santis W, Carello R, et al. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART[J]. AIDS,2006,20(16):2033-2041.
[9]Isgro A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART [J]. Clin Infect Dis,2008, 46(12):1902-1910.
[10]Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy [J]. J Infect Dis,2000, 181(1):141-147.
[11]Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen [J]. AIDS, 1999,13(6):669-676.
[12]FDA. Guidance for industry-patient-reported outcome measures:use in medical product development to support labeling claims, draft guidance. Health Qual Life,2006,4:79.
[13]王艳宏,刘中申,关枫,等.西洋参及其制剂的免疫调节作用研究[J].中医药学刊,2004,22(3)：566-567.
[14]张娴,力曙.中药防治艾滋病研究进展[J].中国中医药信息杂志,2000,7(1)：20-22.
[15]郭宏春,高继全,习欠云,等.冬虫夏草研究进展[J].微生物学杂志,2003,23(1)：50-55.
[16]Prisco A, Bonomi G, Moschela F, et al. In vitro immunization with a recombinant antigen carrying the HIV-1 RT248-262 determinant inserted at diferent locations results in altered TCRVB region usage[J]. Hum Immunol,1999, 60(9):755-763.
[17]Raaphorst FM, Schelonka RL, RusnakJ, et al. CRVBCDR3 diversity of CD4 an d CD8 T-lymphocytes in HIV-infected individuals[J]. Hum Immunol,2002, 63(1):51-60.
[18]Jamie D.K. Wilson, Graham S. Ogg, Rachel L. Allen. Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific[J]. JEM,1998,188(4): 785-790
[19]S. Ramzaoui,F.Jouen-beades,F.Michot,et al.Comparison of activation marker and TCR Vβ gene product expression by CD4+ and CD8+ T cells in peripheral blood and lymph nodes from HIV-infected patients[J]. Clinical & Experimental Immunology,2008,99(2):182-188.
[20]Mark Connors, Joseph A. Kovacs, Seth Krevat, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Medicine,1997,60(3):533-540.
[21]M.Roglic, R.D.Macphee,S.R. Duncan,et al. T cell receptor (TCR) BV gene repertoires and clonal expansions of CD4 cells in patients with HIV infections[J]. Clinical & Experimental Immunology,2003,107(1):21-30.
[22]Li Yin, Zhong Chen Kou, Carina Rodriguez, et al. Antiretroviral Therapy Restores Diversity in the T-Cell Receptor vβ Repertoire of CD4 T-Cell Subpopulations among Human Immunodeficiency Virus Type 1-Infected Children and Adolescents[J]. Clinical and Vaccine Immunology,2009,16(9):1293-1301.
[23]Hongbing Yang, Tao Dong, Emma Turnbull, et al.Broad TCR Usage in Functional HIV-1-Specific CD8+ T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy[J]. The Journal of Immunology,2007, 17(9):597-606.
[24]Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity [J]. Nature,1997, 388 (6640):394-397.
[25]汤艳莉,王阶.Toll样受体及其通路是中医药干预艾滋病免疫重建的可能作用靶点[J].中国中西医结合杂志,2010,30(6)：665-668.
[26]Kanehisa M, Goto S:KEGG:Kyoto Encyclopedia of Genes and Genomes[J]. Nucleic Acids Res,2000,28(1):27-30.
[27]Wagner H, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity[J]. Curr Opin Microbiol,2002,5(1):62-69.
[28]Schlaepfer E, Audige A, von Beust B, et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo[J]. J Virol,2004,78 (22):12344-12354.
[29]AhmadNejad P, Hacker H, Rutz MP, et al. Bacterial CpG-DNA and lipoploysaccharides activate Toll-like receptors at distinct cellular compartments[J]. Eur J Immunol,2002,32(7):1958-1968.
[30]Scagnolari C, Selvaggi C, Chiavuzzo L, et al. Expression Levels of TLRs Involved in Viral Recognition in PBMCs from HIV-1-Infected Patients Failing Antiretroviral Therapy [J]. Intervirology,2009,52:107-114.
[31]汤艳莉,王阶.“以平为期”理念在艾滋病免疫失调调节中的应用[J].2011,26(5)：915-918.
[32]彭广华,贺新怀,席孝贤,等.从Toll样受体探讨中药抗感染免疫作用机制[J].2006,24(11)：2084-2085.
[33]Uciechowski P, Imhoff H,Lange C, et al. Susceptibility to tuberculosis is associated with TLR1 polymorphisms resulting in a lack of TLR1 cell surface expression[J]. J Leukoc Biol,2011,90(2):377-88.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |